December 10, 2004
Lipitor Patent to be Reexamined at PUBPAT'S RequestTopics: Medical Patent Information
8/12/2004 09:16 GMT. ag-IP-news.
NEW YORK - The United States Patent and Trademark Office (USPTO) has issued on Wednesday an Order granting the Public Patent Foundation's (PUBPAT) Request for Reexamination of Pfizer's patent on Lipitor.
A press release by the Foundation stated that Lipitor is touted by the pharmaceutical giant as being "the best-selling treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the world."
In its Order, the USPTO found that PUBPAT's request raised "a substantial new question of patentability" regarding all 44 claims of the patent.
During the past year, Pfizer filed numerous infringement lawsuits asserting the patent against websites offering generic or lower priced versions of Lipitor.
Meanwhile, a one-month supply of Lipitor in New York costs from $105 to $132 and filings with the Securities and Exchange Commission show that Pfizer made $2.4B from the sale of Lipitor in just the second quarter of 2004 alone.
When it requested the reexamination in September, PUBPAT argued that "millions of Americans are not getting the cholesterol lowering treatment they need and deserve because the price for Lipitor is too high." Read More...
Posted by Hyscience at December 10, 2004 10:55 PM
Articles Related to Medical Patent Information: